Recombinant DNA. The Grantee and Sponsoring Institution acknowledge that the statement in the Application to LLS, concerning recombinant DNA and the safeguards to be employed, are accurate descriptions of the circumstances pertaining to this aspect of the research proposed in the Application to LLS. Projects which do not involve recombinant DNA must so state. Failure to notify LLS of non- compliance with these guidelines on the use of recombinant DNA will result in suspension or termination of this Grant.
Appears in 24 contracts
Samples: Cancer Grant Agreement, Translational Research Program Grant Agreement, Special Fellow Grant Agreement
Recombinant DNA. The Grantee and Sponsoring Institution acknowledge that the statement in the Application to LLS, concerning recombinant DNA and the safeguards to be employed, are employed is an accurate descriptions description of the circumstances pertaining to this aspect of the research proposed in the Application to LLSApplication. Projects which do not involve recombinant DNA must so statestate in the Application. Failure to notify LLS of non- non-compliance with these guidelines on the use of recombinant DNA will result in suspension or termination of this GrantAgreement.
Appears in 4 contracts
Samples: Translational Research Program Renewal Grant Agreement, Program Grant Agreement, New Idea Award Grant Agreement
Recombinant DNA. The Grantee and Sponsoring Institution acknowledge that the statement in the Application to LLS, concerning recombinant DNA and the safeguards to be employed, are accurate descriptions of the circumstances pertaining to this aspect of the research proposed in the Application to LLS. Projects which do not involve recombinant DNA must so state. Failure to notify LLS of non- non-compliance with these guidelines on the use of recombinant DNA will result in suspension or termination of this Grant.
Appears in 2 contracts
Samples: Grant Agreement, Grant Agreement
